The MYTSV Mission and Concept MYTSV.com (Meet Your Town Specialists) is rewriting the rules of local discovery. Its mission is to simplify and enhance the way people find services by bridging the gap ...

Background Azithromycin mass drug administration (MDA) to ages 1–59 months can reduce childhood mortality; however, more ...

A study has found that discontinuing obesity medications such as Wegovy or Mounjaro leads to weight regain four times faster ...

For further information on the two studies, please see Biofrontera’s press releases 3,4 from September 16, 2025, and August 25, 2025. The 1-year follow-up phase of the phase III study on AK is still ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...

Introduction Cancer care in humanitarian settings is very challenging, and patients may face significant barriers to ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) shared topline data from the ESSENCE Phase 3 trial of Amondys 45 (casimersen) and Vyondys 53 (golodirsen) compared with placebo in 225 patients aged 6-13 years ...

ABSTRACT: Special education services are designed to provide tailored support for students with diverse learning needs, with the expectation of improving academic achievement. This study examines the ...

Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...